RxDoctor Payments Data

Thomas de Miranda, MD

Interventional Pain Medicine · Fort Smith, ARNPI 1689866725

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 56.5% of the total. Reporting peaked in 2024 at $2,899 and has fallen 70.1% since, to $866 in 2025.

$4,000in general payments, 2019–2025

Across 68 payments — averaging $58.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Tersera Therapeutics LLC$584
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$313
  • Averitas Pharma Inc.$247
  • Gilead$145
  • Collegium Pharmaceutical, Inc.$105
  • plus $346 from 11 others

What the payments were for

  • Travel & lodging$2,14154%
  • Food & beverage$1,49937%
  • Education$3619%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,000 in reported general payments places this provider in the 55th percentile of 29 interventional pain medicine providers in Arkansas.

See all interventional pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$382,862
Medicare patients
296
Services billed
4,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl248$162,041
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,608$45,858
RelistorMethylnaltrexone Bromide13$37,558
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,001$28,490
Oxycodone Hcl1,413$23,400
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl62$13,668
OxycontinOxycodone Hcl18$9,567
ButransBuprenorphine22$8,945
Buprenorphine27$8,697
Xtampza ErOxycodone Myristate24$7,847
Pregabalin504$6,939
Naloxone Hcl51$3,977
Gabapentin332$3,497
Tizanidine Hcl268$3,314
Buprenorphine Hcl124$3,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$105$169,889272 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$313$37,55813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 29 interventional pain medicine providers in Arkansas.

Other interventional pain medicine in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →